{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:47:04Z","timestamp":1793674024843,"version":"4.5.1"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lanepe.2026.101837","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:47:43Z","timestamp":1788479263000},"page":"101837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Changing epidemiology and etiology of hepatocellular carcinoma in Europe: implications for clinical practice and health policy"],"prefix":"10.1016","volume":"70","author":[{"given":"Bernhard","family":"Scheiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-1845","authenticated-orcid":false,"given":"Fabio","family":"Piscaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta Anesti","family":"Kondili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Procopet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1324-7497","authenticated-orcid":false,"given":"Shira","family":"Zelber-Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: Global Burden of Disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J Hepatol"},{"issue":"10504","key":"10.1016\/j.lanepe.2026.101837_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/liv.15446","article-title":"Securing wider EU commitment to the elimination of hepatitis C virus","volume":"43","author":"Wedemeyer","year":"2023","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2023.12.031","article-title":"Inequities in primary liver cancer in Europe: the state of play","volume":"80","author":"Kondili","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101837_bib8","author":"Ferlay"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101837_bib9","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1097\/MS9.0000000000003433","article-title":"Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study","volume":"87","author":"Kazi","year":"2025","journal-title":"Ann Med Surg"},{"issue":"10319","key":"10.1016\/j.lanepe.2026.101837_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.35097","article-title":"Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: a nationwide cohort study","volume":"156","author":"Vaz","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lanepe.2026.101837_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2026.101924","article-title":"Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort","author":"van Son","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.lanepe.2026.101837_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2025.102976","article-title":"Etiologic profile and prognostic patterns of hepatocellular carcinoma in a Southern European population - madeira, Portugal: insight into a preventable cancer","volume":"100","author":"Berenguer","year":"2026","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15403\/jgld-6114","article-title":"The role of easy-to-use non-invasive scores in the assessment of hepatocellular carcinoma prognosis - data from the Romanian hepatocellular carcinoma registry","volume":"34","author":"Cri\u015fan","year":"2025","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.14735\/amgh201899","article-title":"Hepatocellular carcinoma in central Slovakia \u2013 tertiary referral centre experience with 207 patients","volume":"72","author":"Skladan\u00fd","year":"2018","journal-title":"Gastroent Hepatol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101837_bib17","article-title":"Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: a challenge for surveillance?","volume":"7","author":"Pasta","year":"2025","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib18","article-title":"Evolving epidemiology of HCC in Spain","volume":"7","author":"Sala","year":"2025","journal-title":"JHEP Rep"},{"issue":"21","key":"10.1016\/j.lanepe.2026.101837_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215215","article-title":"Changes in the epidemiology of hepatocellular carcinoma in Carinthia, Austria, 2012-2023","volume":"15","author":"Hucke","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lanepe.2026.101837_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251363202","article-title":"Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study","volume":"17","author":"Schrodi","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/MEG.0000000000002982","article-title":"Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy","volume":"37","author":"Nguyen-Khac","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41416-021-01509-4","article-title":"Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England","volume":"126","author":"Burton","year":"2022","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cam4.4551","article-title":"Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"issue":"10541","key":"10.1016\/j.lanepe.2026.101837_bib24","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(26)00138-8","article-title":"Implementing sustainable liver health in Europe: a second EASL-Lancet Commission","volume":"407","author":"Karlsen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101837_bib25","series-title":"Hepatitis B vaccination policies, practices and challenges to achieving hepatitis elimination in the European Union and European Economic Area","year":"2025"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.70360","article-title":"Prediction of hepatocellular carcinoma and other liver-related events in chronic hepatitis B patients with metabolic dysfunction or metabolic dysfunction-associated steatotic liver disease","volume":"63","author":"Patmore","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101837_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13100841","article-title":"Hepatitis C virus infection in Europe","volume":"13","author":"Simao","year":"2024","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jvh.13899","article-title":"Epidemiology of hepatitis D virus infection in Europe: is it vanishing?","volume":"31","author":"Demirel","year":"2024","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"26","key":"10.1016\/j.lanepe.2026.101837_bib30","first-page":"00058","article-title":"The changing epidemiology of primary liver cancer in the 21st century","volume":"S0168-8278","author":"Khan","year":"2026","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib32","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.cgh.2022.07.009","article-title":"Contemporary changes in etiology for hepatocellular carcinoma in liver transplantation","volume":"21","author":"Goff","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100876","article-title":"Changing epidemiology of hepatocellular carcinoma in South America: a report from the South American liver research network","volume":"28","author":"Farah","year":"2023","journal-title":"Ann Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12072-026-11037-z","article-title":"Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia","volume":"20","author":"Takeuchi","year":"2026","journal-title":"Hepatol Int"},{"key":"10.1016\/j.lanepe.2026.101837_bib36","series-title":"Epidemiological assessment of hepatitis B and C among migrants in the EU\/EEA","year":"2016"},{"key":"10.1016\/j.lanepe.2026.101837_bib37","article-title":"Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study","volume":"58","author":"Razavi-Shearer","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2471\/BLT.20.260919","article-title":"Improving care of migrants is key for viral hepatitis elimination in Europe","volume":"99","author":"Kim","year":"2021","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jhep.2023.10.019","article-title":"Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe","volume":"80","author":"Patmore","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lanepe.2026.101837_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1368980026102687","article-title":"Obesity and the experienced cultural, economic, and climate variations among immigrants to high-income countries: an umbrella review of the literature","volume":"29","author":"Abed Al Ahad","year":"2026","journal-title":"Public Health Nutr"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11739-015-1302-9","article-title":"Disparities in type 2 diabetes prevalence among ethnic minority groups resident in Europe: a systematic review and meta-analysis","volume":"11","author":"Meeks","year":"2016","journal-title":"Intern Emerg Med"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib43","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/hep4.1974","article-title":"Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: a national register study","volume":"6","author":"Duberg","year":"2022","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101837_bib44","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1016\/S2468-2667(22)00174-8","article-title":"Prevention and treatment of infectious diseases in migrants in Europe in the era of universal health coverage","volume":"7","author":"Baggaley","year":"2022","journal-title":"Lancet Public Health"},{"issue":"20","key":"10.1016\/j.lanepe.2026.101837_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204638","article-title":"Prevalence of the absence of cirrhosis in subjects with NAFLD-associated hepatocellular carcinoma","volume":"10","author":"Castellana","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib46","article-title":"Hepatocellular carcinoma risk scores for non-viral liver disease: a systematic review and meta-analysis","volume":"7","author":"Burke","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.lanepe.2026.101837_bib47","doi-asserted-by":"crossref","DOI":"10.2147\/JHC.S561956","article-title":"HCC is the predominant liver-related event in MASLD: 2-Step non-invasive algorithms to stratify risk in non-cirrhotic patients","volume":"13","author":"Indre","year":"2026","journal-title":"J Hepatocell Carcinoma"},{"issue":"17","key":"10.1016\/j.lanepe.2026.101837_bib48","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic Fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cgh.2023.05.024","article-title":"Hepatocellular carcinoma incidence threshold for surveillance in virologically cured hepatitis C individuals","volume":"22","author":"Chhatwal","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cgh.2023.06.026","article-title":"Regional differences in clinical presentation and prognosis of patients with post-sustained virologic response hepatocellular carcinoma","volume":"22","author":"Toyoda","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib51","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00261-022-03702-2","article-title":"HCC screening with ultrasound: assessment of quality using ultrasound LI-RADS score","volume":"48","author":"King","year":"2023","journal-title":"Abdom Radiol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib53","article-title":"Practice changing RCT design and rationale: abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)","volume":"8","author":"Ioannou","year":"2026","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib54","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/HEP.0000000000000027","article-title":"Model to predict major complications following liver resection for HCC in patients with metabolic syndrome","volume":"77","author":"Berardi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib55","article-title":"NAFLD and liver transplantation: disease burden, current management and future challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib56","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1097\/TP.0000000000005519","article-title":"Physical frailty and Sarcopenia in liver transplantation: how should they be assessed and addressed?","volume":"110","author":"Ngonadi","year":"2026","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2023.10.029","volume":"56","author":"Cabibbo","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib58","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1097\/SLA.0000000000005861","article-title":"Minimally invasive versus open liver resections for hepatocellular carcinoma in patients with metabolic syndrome","volume":"278","author":"Berardi","year":"2023","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib59","article-title":"Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: an Italian liver transplant registry study","volume":"6","author":"Vitale","year":"2024","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib60","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jhep.2023.05.034","article-title":"Natural history of NASH cirrhosis in liver transplant waitlist registrants","volume":"79","author":"Lim","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.dld.2024.09.025","article-title":"Liver transplant for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease versus other etiologies: a meta-analysis","volume":"57","author":"Parente","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2015.01.024","article-title":"Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC","volume":"63","author":"Vigano","year":"2015","journal-title":"J Hepatol"},{"issue":"10515","key":"10.1016\/j.lanepe.2026.101837_bib64","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100338","article-title":"Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management","volume":"7","author":"Vallerio","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lanepe.2026.101837_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1213771","article-title":"Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination","volume":"3","author":"Niimura","year":"2023","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.lanepe.2026.101837_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102365","article-title":"Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma","volume":"70","author":"Peeters","year":"2023","journal-title":"Curr Opin Pharmacol"},{"issue":"7854","key":"10.1016\/j.lanepe.2026.101837_bib68","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib69","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101837_bib70","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"9865","key":"10.1016\/j.lanepe.2026.101837_bib71","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib72","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/MCG.0000000000000162","article-title":"Cirrhosis regression in patients with viral hepatitis B and C: a systematic review","volume":"48","author":"Manne","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"5 Pt 1","key":"10.1016\/j.lanepe.2026.101837_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"issue":"S1","key":"10.1016\/j.lanepe.2026.101837_bib74","first-page":"2S1","article-title":"Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial; LBO-001","volume":"8","author":"Trauner","year":"2025"},{"issue":"21","key":"10.1016\/j.lanepe.2026.101837_bib75","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib76","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib77","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.cgh.2025.08.010","article-title":"Prevalence and clinical outcomes of recompensation in decompensated cirrhosis: a systematic review and meta-analysis","volume":"24","author":"Goh","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib78","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib79","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101837_bib80","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gutjnl-2025-334928","article-title":"Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction","volume":"74","author":"Pinter","year":"2025","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib81","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.lanepe.2026.101837_bib82","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.cgh.2024.12.028","article-title":"Liver decompensation in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a real-life study","volume":"23","author":"Stella","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101837_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70362","article-title":"Hepatitis C eradication improves oncologic and clinical outcomes in patients treated with atezolizumab plus bevacizumab","volume":"45","author":"Stella","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.lanepe.2026.101837_bib84","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1007\/s00330-025-12135-6","article-title":"Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis","volume":"36","author":"Zheng","year":"2026","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib85","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70092","article-title":"Hepatic recompensation before systemic therapy for hepatocellular carcinoma yields comparable survival to compensated cirrhosis","volume":"45","author":"Pinero","year":"2025","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101837_bib86","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2010.04414.x","article-title":"Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma","volume":"32","author":"Singal","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib87","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101837_bib88","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70311","article-title":"Managing MASLD through preventive hepatology: integrating policy reform, public health and personalised care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib89","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S2468-1253(26)00015-4","article-title":"The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission","volume":"11","author":"Jarvis","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000229","article-title":"HBV elimination in Europe: current status and challenges","volume":"23","author":"Buti","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.lanepe.2026.101837_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2026.106360","article-title":"Hepatitis C virus elimination: so close, so far?","volume":"247","author":"Pawlotsky","year":"2026","journal-title":"Antiviral Res"},{"key":"10.1016\/j.lanepe.2026.101837_bib92","series-title":"Action plan for the health sector response to viral hepatitis in the WHO European Region","year":"2017"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3350\/cmh.2020.0176","article-title":"Obesity and the risk of primary liver cancer: a systematic review and meta-analysis","volume":"27","author":"Sohn","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101837_bib94","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.cgh.2020.01.003","article-title":"High dietary intake of vegetable or polyunsaturated fats is associated with reduced risk of hepatocellular carcinoma","volume":"18","author":"Yang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101837_bib95","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10654-021-00741-9","article-title":"Consumption of red meat and processed meat and cancer incidence: a systematic review and meta-analysis of prospective studies","volume":"36","author":"Farvid","year":"2021","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib96","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.2023.12618","article-title":"Sugar-sweetened and artificially sweetened beverages and risk of liver cancer and chronic liver disease mortality","volume":"330","author":"Zhao","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101837_bib97","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2018.12.014","article-title":"Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study","volume":"70","author":"Baumeister","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib98","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jhep.2013.10.034","article-title":"Mediterranean diet and hepatocellular carcinoma","volume":"60","author":"Turati","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2026.101837_bib99","unstructured":"World Cancer Research Fund\/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and liver cancer. Available at: dietandcancerreport.org."},{"issue":"10","key":"10.1016\/j.lanepe.2026.101837_bib100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","article-title":"Food inequity and insecurity and MASLD: burden, challenges, and interventions","volume":"21","author":"Zelber-Sagi","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101837_bib101","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2468-1253(24)00220-6","article-title":"Best buy interventions to address the burden of steatotic liver disease","volume":"9","author":"Lazarus","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib102","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2468-1253(25)00300-0","article-title":"Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study","volume":"11","author":"Lazarus","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","article-title":"Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes","volume":"80","author":"Diaz","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib104","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","article-title":"Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study","volume":"80","author":"Retat","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2026.101837_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2024.108087","article-title":"Effectiveness of alcohol warning labels for at-risk groups and the general public: a policy-informing randomized experiment in Chile","volume":"187","author":"Schwartz","year":"2024","journal-title":"Prev Med"},{"key":"10.1016\/j.lanepe.2026.101837_bib106","article-title":"On-label alcohol beverage warnings in Ireland- setting a standard for Europe","volume":"50","author":"Murray","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101837_bib107","series-title":"The SAFER technical package: five areas of intervention at national and subnational levels","year":"2019"},{"key":"10.1016\/j.lanepe.2026.101837_bib108","series-title":"Empowering public health advocates to navigate alcohol policy challenges: alcohol policy playbook","year":"2024"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101837_bib109","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41575-025-01084-6","article-title":"Public health policies to prevent alcohol-related liver disease","volume":"22","author":"Parker","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib110","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.14309\/ajg.0000000000002749","article-title":"Food insecurity, low household income, and low education level increase the risk of having metabolic dysfunction-associated Fatty liver disease among adolescents in the United States","volume":"119","author":"Paik","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101837_bib111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2024.08.011","article-title":"Association of food insecurity with MASLD prevalence and liver-related mortality","volume":"82","author":"Younossi","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101837_bib112","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cgh.2024.08.053","article-title":"Food swamps and food deserts impact on metabolic dysfunction-associated steatotic liver disease mortality in US counties","volume":"23","author":"Paik","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101837_bib113","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/jamaoncol.2023.0634","article-title":"Association of food deserts and food swamps with obesity-related cancer mortality in the US","volume":"9","author":"Bevel","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib114","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00394-021-02733-7","article-title":"Ultra-processed food consumption in adults across Europe","volume":"61","author":"Mertens","year":"2022","journal-title":"Eur J Nutr"},{"issue":"10520","key":"10.1016\/j.lanepe.2026.101837_bib115","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/S0140-6736(25)01565-X","article-title":"Ultra-processed foods and human health: the main thesis and the evidence","volume":"406","author":"Monteiro","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib116","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1368980017000234","article-title":"The UN decade of nutrition, the NOVA food classification and the trouble with ultra-processing","volume":"21","author":"Monteiro","year":"2018","journal-title":"Public Health Nutr"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101837_bib117","first-page":"e245","article-title":"Ultraprocessed foods and their association with cardiometabolic health: evidence, gaps, and opportunities: a science advisory from the American Heart Association","volume":"152","author":"Vadiveloo","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib118","article-title":"Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: a systematic review","volume":"6","author":"Grinshpan","year":"2024","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib119","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajcnut.2023.10.014","article-title":"Higher ultra-processed food intake is associated with adverse liver outcomes: a prospective cohort study of UK Biobank participants","volume":"119","author":"Zhao","year":"2024","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101837_bib120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.lanepe.2026.101837_bib121","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101837_bib122","first-page":"245","article-title":"American Cancer Society guideline for diet and physical activity for cancer prevention","volume":"70","author":"Rock","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"10520","key":"10.1016\/j.lanepe.2026.101837_bib123","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/S0140-6736(25)01566-1","article-title":"Policies to halt and reverse the rise in ultra-processed food production, marketing, and consumption","volume":"406","author":"Scrinis","year":"2025","journal-title":"Lancet"},{"issue":"10520","key":"10.1016\/j.lanepe.2026.101837_bib124","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/S0140-6736(25)01567-3","article-title":"Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response","volume":"406","author":"Baker","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101837_bib125","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/s41591-022-02027-3","article-title":"A food is medicine approach to achieve nutrition security and improve health","volume":"28","author":"Mozaffarian","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101837_bib126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43856-023-00398-3","article-title":"Integrating social nutrition principles into the treatment of steatotic liver disease","volume":"3","author":"Ivancovsky-Wajcman","year":"2023","journal-title":"Commun Med"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101837_bib127","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project","volume":"118","author":"Petrick","year":"2018","journal-title":"Br J Cancer"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:18:51Z","timestamp":1793632731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":125,"alternative-id":["S2666776226002498"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101837","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing epidemiology and etiology of hepatocellular carcinoma in Europe: implications for clinical practice and health policy","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101839","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101861","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101852","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101837"}}